An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAF V600-mutant melanoma a subgroup analysis of patients with brain metastasis

Home / Abstract / An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAF V600-mutant melanoma a subgroup analysis of patients with brain metastasis